Beehive_BKK的个人主页 - 老虎社区

Beehive_BKK

Beehive_BKK

暂无个人介绍

IP属地：未知

3关注

1粉丝

0主题

0勋章

2021-04-29

เซม

@DWP:$HUMBL Inc.(HMBL)$bleeeeeeding 😪

2021-03-15

🙏🏻

Better Buy: NIO vs. XPeng Motors

2021-03-04

Hmmmmm

Facebook ends ban on political advertising across its network

2021-03-04

👌🏻

Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3576882204250083","uuid":"3576882204250083","gmtCreate":1613788868700,"gmtModify":1613789950950,"name":"Beehive_BKK","pinyin":"beehivebkkbeehivebkk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574652001822174","authorIdStr":"3574652001822174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","pubTimestamp":1615771321,"share":"https://www.laohu8.com/m/news/1161179297?lang=&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p>\n<p>Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p>\n<p>EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p>\n<p><b>The right market</b></p>\n<p>As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p>\n<p>NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p>\n<p>XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p>\n<p>NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p>\n<p><b>Priced for perfection</b></p>\n<p>The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p>\n<p>Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p>\n<p>Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p>\n<p><b>Looking ahead</b></p>\n<p>NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p>\n<p>Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p>\n<p>For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 09:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"repost":{"id":"2116152999","pubTimestamp":1614812749,"share":"https://www.laohu8.com/m/news/2116152999?lang=&edition=full","pubTime":"2021-03-04 07:05","market":"us","language":"en","title":"Facebook ends ban on political advertising across its network","url":"https://stock-news.laohu8.com/highlight/detail?id=2116152999","media":"The Straits Times","summary":"SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across i","content":"<div>\n<p>SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook ends ban on political advertising across its network</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook ends ban on political advertising across its network\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-04 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2116152999","content_text":"SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading misinformation, falsehoods and inflaming voters.The social network said on Wednesday (March 3) that it would allow advertisers to buy new ads about \"social issues, elections or politics\" beginning Thursday, according to a copy of an e-mail sent to political advertisers and viewed by The New York Times.Those advertisers must complete a series of identity checks before being authorised to place the ads, the company said.\"We put this temporary ban in place after the November 2020 election to avoid confusion or abuse following Election Day,\" Facebook said in a blog post. \"We've heard a lot of feedback about this and learnt more about political and electoral ads during this election cycle. As a result, we plan to use the coming months to take a closer look at how these ads work on our service to see where further changes may be merited.\"Mr Mark Zuckerberg, Facebook's chief executive, has said he wished to maintain a largely hands-off stance towards speech on the site unless it posed an immediate harm to the public or individuals.Former president Donald Trump used Facebook's political ads to amplify claims about an \"invasion\" on the Mexican border in 2019, among other incidents.Facebook banned political ads late last year as a way to choke off misinformation and threats of violence around the November presidential election.In January, Facebook banned Mr Trump from using his account and posting on the platform after he took to social media to delegitimise the election results and incited a violent uprising among his supporters, who stormed the US Capitol.Facebook said Mr Trump's suspension was indefinite. The decision is under review by the Facebook Oversight Board, a third-party entity created by the company and composed of journalists, academics and others that adjudicates some of the company's thorny content policy enforcement decisions. A decision is expected within the next few months.On Thursday, political advertisers on Facebook will be able to submit new ads or turn on existing political ads that have already been approved, the company said. Each ad will appear with a small disclaimer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohu8.com/m/news/1172714394?lang=&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-03 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":364880038,"gmtCreate":1614833458024,"gmtModify":1703481731661,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"Hmmmmm","listText":"Hmmmmm","text":"Hmmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/364880038","repostId":"2116152999","repostType":4,"repost":{"id":"2116152999","pubTimestamp":1614812749,"share":"https://www.laohu8.com/m/news/2116152999?lang=&edition=full","pubTime":"2021-03-04 07:05","market":"us","language":"en","title":"Facebook ends ban on political advertising across its network","url":"https://stock-news.laohu8.com/highlight/detail?id=2116152999","media":"The Straits Times","summary":"SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across i","content":"<div>\n<p>SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook ends ban on political advertising across its network</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook ends ban on political advertising across its network\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-04 07:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.straitstimes.com/world/united-states/facebook-ends-ban-on-political-advertising-across-its-network","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2116152999","content_text":"SAN FRANCISCO (NYTIMES) - Facebook said it planned to lift its ban on political advertising across its network, resuming a form of digital promotion that has been criticised for spreading misinformation, falsehoods and inflaming voters.The social network said on Wednesday (March 3) that it would allow advertisers to buy new ads about \"social issues, elections or politics\" beginning Thursday, according to a copy of an e-mail sent to political advertisers and viewed by The New York Times.Those advertisers must complete a series of identity checks before being authorised to place the ads, the company said.\"We put this temporary ban in place after the November 2020 election to avoid confusion or abuse following Election Day,\" Facebook said in a blog post. \"We've heard a lot of feedback about this and learnt more about political and electoral ads during this election cycle. As a result, we plan to use the coming months to take a closer look at how these ads work on our service to see where further changes may be merited.\"Mr Mark Zuckerberg, Facebook's chief executive, has said he wished to maintain a largely hands-off stance towards speech on the site unless it posed an immediate harm to the public or individuals.Former president Donald Trump used Facebook's political ads to amplify claims about an \"invasion\" on the Mexican border in 2019, among other incidents.Facebook banned political ads late last year as a way to choke off misinformation and threats of violence around the November presidential election.In January, Facebook banned Mr Trump from using his account and posting on the platform after he took to social media to delegitimise the election results and incited a violent uprising among his supporters, who stormed the US Capitol.Facebook said Mr Trump's suspension was indefinite. The decision is under review by the Facebook Oversight Board, a third-party entity created by the company and composed of journalists, academics and others that adjudicates some of the company's thorny content policy enforcement decisions. A decision is expected within the next few months.On Thursday, political advertisers on Facebook will be able to submit new ads or turn on existing political ads that have already been approved, the company said. Each ad will appear with a small disclaimer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":322112539,"gmtCreate":1615782451321,"gmtModify":1703492874861,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322112539","repostId":"1161179297","repostType":4,"repost":{"id":"1161179297","pubTimestamp":1615771321,"share":"https://www.laohu8.com/m/news/1161179297?lang=&edition=full","pubTime":"2021-03-15 09:22","market":"us","language":"en","title":"Better Buy: NIO vs. XPeng Motors","url":"https://stock-news.laohu8.com/highlight/detail?id=1161179297","media":"Motley Fool","summary":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.Stocks of electric-vehicle  makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach","content":"<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.</p>\n<p>Stocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.</p>\n<p>EV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are&nbsp;<b>NIO</b>&nbsp;(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>&nbsp;(NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.</p>\n<p><b>The right market</b></p>\n<p>As noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.<b>Tesla</b>&nbsp;(NASDAQ:TSLA)&nbsp;built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that&nbsp;<b>BYD</b>&nbsp;(OTC:BYDDY)&nbsp;sold in 2020.</p>\n<p>NIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.</p>\n<p>XPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.</p>\n<p>NIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.</p>\n<p><b>Priced for perfection</b></p>\n<p>The strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.</p>\n<p>Neither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The&nbsp;price-to-sales ratios&nbsp;(P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cf721bd77e4fa0e2530b3d2f86034920\" tg-width=\"720\" tg-height=\"483\"><span>NIO MARKET CAP DATA BY YCHARTS</span></p>\n<p>Though NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.</p>\n<p><b>Looking ahead</b></p>\n<p>NIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.</p>\n<p>Both companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by&nbsp;listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.</p>\n<p>For investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Buy: NIO vs. XPeng Motors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Buy: NIO vs. XPeng Motors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 09:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://www.fool.com/investing/2021/03/14/better-buy-nio-vs-xpeng-motors/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161179297","content_text":"The Chinese electric-vehicle makers both have rich valuations, even after a downturn in share prices.\nStocks of electric-vehicle (EV) makers accelerated in 2020. And it's no secret that Chinese EV stocks were some of the most popular, as the largest automotive market in the world continues to move toward electrification in its transportation sector.\nEV sales in China surpassed 1 million in 2020, and the government hopes to grow that to 5 million by 2025. It could reach 10 million by 2030, and approach 20 million by 2040, according to research organization BloombergNEF. Two electric automakers looking to capitalize on that expansion are NIO (NYSE:NIO) and XPeng (NYSE:XPEV). Investors may be wondering which is the better buy, particularly after a correction has hit share prices in the sector.\nThe right market\nAs noted above, the largest automotive market in the world has much potential forEV growth. The problem is, there will be plenty of companies seeking to capitalize.Tesla (NASDAQ:TSLA) built its second manufacturing plant in Shanghai for a reason. And though they're maybe the most well-known Chinese EV makers, NIO and XPeng combined delivered only slightly more than half the 131,000 battery-electric vehicles that BYD (OTC:BYDDY) sold in 2020.\nNIO reached almost 44,000 vehicles delivered in 2020, while XPeng more than doubled its volume versus 2019 to 27,041. Both companies have recently introduced sedan models that each hopes will be significant drivers of future sales growth.\nXPeng's P7 sports sedan has surpassed a total of 20,000 cumulative deliveries since its launch in early 2020, as it moves ahead of the G3 compact SUV as the company's most popular vehicle. That marked the fastest pace to 20,000 vehicle deliveries of any Chinese EV start-up.\nNIO introduced its new ET7 luxury sedan earlier this year. The ET7 will be available early next year, and has some intricate features. The sleek exterior includes autonomous driving sensors, a \"crystal-like heartbeat\" tail light, all-glass roof, and a digital entry system that extends the flush handle and automatically releases the door's \"e-latch\" as the driver approaches.\nPriced for perfection\nThe strong sales growth along with massive potential for Chinese EVs had investors already piling into these stocks. But after shares of both NIO and XPeng soared last year, the stocks are off January 2021 highs by 27% and 38% respectively, making now a good time to see which may be the better buy.\nNeither company is profitable yet, so one way to measure valuations is using sales rather than earnings. The price-to-sales ratios (P/S) are both very high, but sales are expected to grow quickly, and it's a relevant metric for comparing the two companies.\nNIO MARKET CAP DATA BY YCHARTS\nThough NIO has the higher market cap, it is less expensive than XPeng as measured by the P/S ratio. NIO also has a unique approach to the market with its battery swap program, which allows customers to \"recharge\" via a faster battery exchange. The company says its automated battery swap stations take only three minutes to produce a fully charged battery replacement.\nLooking ahead\nNIO's push into the luxury sedan segment with its ET7 could help advance the company to the next level. Gross margins, gross profit, and operating cash flow went positive in 2020, indicating the path to profitability is in sight.\nBoth companies look to be adequately capitalized to fund planned growth efforts. As of Dec. 31, 2020, NIO had $6.5 billion in cash and cash equivalents, restricted cash, and short-term investment on its balance sheet, and XPeng had about $5.4 billion. The companies could raise more money by listing on the Hong Kong Stock Exchange, which is reportedly being considered by both.\nFor investors looking to pick just one holding to participate in Chinese EV growth, NIO appears to be the better option of these two companies. Any investment still belongs in the speculative portion of a portfolio, with the potential for much volatility. But for those who can stomach that, and have an appropriate portion invested, the recent drop in shares helps make NIO a better buy than XPeng right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109695483,"gmtCreate":1619688398542,"gmtModify":1634210712908,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"เซม","listText":"เซม","text":"เซม","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/109695483","repostId":"374290611","repostType":1,"repost":{"id":374290611,"gmtCreate":1619447027033,"gmtModify":1631888271015,"author":{"id":"3574652001822174","authorId":"3574652001822174","name":"DWP","avatar":"https://static.tigerbbs.com/cf842b9e680a5ecebea8472f4a157226","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574652001822174","authorIdStr":"3574652001822174"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","listText":"<a href=\"https://laohu8.com/S/HMBL\">$HUMBL Inc.(HMBL)$</a>bleeeeeeding 😪","text":"$HUMBL Inc.(HMBL)$bleeeeeeding 😪","images":[{"img":"https://static.tigerbbs.com/8b79a88da903c7e0e8036cad05a222bf","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/374290611","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":364834174,"gmtCreate":1614832110998,"gmtModify":1703481713436,"author":{"id":"3576882204250083","authorId":"3576882204250083","name":"Beehive_BKK","avatar":"https://static.tigerbbs.com/d0ecd2a791342d747bbfe4b2ad142240","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576882204250083","authorIdStr":"3576882204250083"},"themes":[],"htmlText":"👌🏻","listText":"👌🏻","text":"👌🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364834174","repostId":"1172714394","repostType":4,"repost":{"id":"1172714394","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614783206,"share":"https://www.laohu8.com/m/news/1172714394?lang=&edition=full","pubTime":"2021-03-03 22:53","market":"us","language":"en","title":"Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172714394","media":"老虎资讯综合","summary":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-develo","content":"<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock soars after partner Bharat Biotech COVID-19 vaccine candidate shows 81% efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-03 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 3)&nbsp;Shares of <a href=\"https://laohu8.com/S/OCGN\">Histogenics</a> soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.</p><p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\" referrerpolicy=\"no-referrer\"></p><p>Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.</p><p>\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.</p><p>\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172714394","content_text":"(March 3) Shares of Histogenics soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%.Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups.\"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri.\"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}